title: Fc gamma receptor-mediated interplatelet activation by a monoclonal antibody against beta 2 microglobulin.
abstract: Three different mAb directed against beta 2 microglobulin (two IgG1 and one IgG2a) were tested for their ability to activate human platelets. Although all three antibodies bound to platelets, only one of them, B2.62.2, of the IgG1 subclass, induced platelet activation. This activation is similar to the activation by SYB-1, a CD9 antibody of the same subclass previously described as activating platelets through platelet Fc gamma R. These similarities include serotonin secretion, a lag time preceding aggregation and the induction of a strong intracellular calcium mobilization from storage pools. As with CD9 antibodies, the F(ab')2 fragments of B2.62.2 did not induce activation but blocked the activation by the native antibody, by preventing the binding to beta 2 microglobulin. Also, this activation was inhibited by pretreating the platelet with IV-3, a mAb that blocks the Fc binding site of the FcR. Inasmuch as the same antibody does not prevent the binding of B2.62.2 on platelets, we conclude that the activation by B2.62.2 is mediated by the FcR. Nevertheless, there were differences with the activation by SYB-1. B2.62.2 activation was more dependent on thromboxane A2 formation and no cytoplasmic alkalinization was detected. Finally, contrary to SYB-1, B2.62.2 activation proved to be sensitive to platelet count, suggesting that it involves the formation of immune complexes consisting of antibodies and platelets, that activate nearby platelets.
authors.affiliation: Department of Medical Biology, University of Tennessee Medical Center, Knoxville 37920.
authors.forename: E
authors.initials: E
authors.lastname: Rubinstein
authors.forename: C
authors.initials: C
authors.lastname: Boucheix
authors.forename: I
authors.initials: I
authors.lastname: Urso
authors.forename: R C
authors.initials: RC
authors.lastname: Carroll
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology*; D000943:Antigens, Differentiation / Q000502:physiology*; D001241:Aspirin / Q000494:pharmacology; D001667:Binding, Competitive; D002118:Calcium / Q000502:physiology; D015550:Cell Degranulation / Q000187:drug effects; D003593:Cytoplasm / Q000502:physiology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D066298:In Vitro Techniques; D010750:Phosphoproteins / Q000378:metabolism; D015539:Platelet Activation; D011940:Receptor Aggregation; D011961:Receptors, Fc / Q000502:physiology*; D017452:Receptors, IgG; D012701:Serotonin / Q000378:metabolism; D001613:beta 2-Microglobulin / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D010750:Phosphoproteins; D011961:Receptors, Fc; D017452:Receptors, IgG; D001613:beta 2-Microglobulin; D012701:Serotonin; D001241:Aspirin; D002118:Calcium